Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

21.08.2018 | short review | Ausgabe 3/2018 Open Access

memo - Magazine of European Medical Oncology 3/2018

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis

memo - Magazine of European Medical Oncology > Ausgabe 3/2018
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Wichtige Hinweise

Authors’ contributions

Conception and design: G. Rinnerthaler; collection and assembly of data: G. Rinnerthaler; data analysis and interpretation: all authors; manuscript writing: G. Rinnerthaler and S. P. Gampenrieder; critical revising of the manuscript: S. P. Gampenrieder, R. Greil; final approval of manuscript: all authors.


This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.
In a retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial investigating ribociclib or placebo in combination with endocrine therapy as first-line treatment in pre- and perimenopausal women with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer, a significantly longer progression-free survival was shown for patients treated with ribociclib compared to the placebo group (23.8 vs. 13.0 months; HR 0.55; 95% CI 0.43–0.72; P < 0.001). In a pooled toxicity and efficacy analysis of elderly women treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in combination with an aromatase inhibitor in first-line, toxicities of higher grade were more common in elderly compared to younger patients, despite comparable efficacy. And the Clinical Treatment Score post-5 years (CTS5), accurately estimated the risk of late recurrence after 5 years of adjuvant endocrine treatment using routinely available clinical parameters.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

memo - Magazine of European Medical Oncology 3/2018 Zur Ausgabe